Catégorie : Essais Cliniques

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties, Rachael L. Sumner et al., 2021

A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties Rachael L. Sumner, Emme Chacko, Rebecca McMillan, Meg J. Spriggs, Christie Anderson, James Chen, Amelia French, SungHun Jung, Akshaya Rajan, Gemma Malpas, John Hay, Rhys Ponton, Suresh D. Muthukumaraswamy and Frederick Sundram Journal of Psychopharmacology, 2021, 1-16 Doi : 10.1177/0269881121998321 Abstract Background : Ketamine is central to one of the most rapidly growing areas of neuroscientific research into novel treatments for depression. Limited research has indicated that the psychedelic properties of ketamine may play a role in its antidepressant effects. Aim : The aim of the current study was to explore the [...]

Lire la suite

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease, Stephanie Martins de Faria et al., 2020

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson’s disease Stephanie Martins de Faria, Daiene de Morais Fabrício, Vitor Tumas, Paula Costa Castro, Moacir Antonelli Ponti, Jaime E.C. Hallak, Antonio W. Zuardi, José Alexandre S. Crippa and Marcos Hortes Nisihara Chagas Journal of Psychopharmacology, 2020, 1–8 doi : 10.1177/0269881119895536   Abstract Background : Cannabidiol (CBD) is one of the main components of Cannabis sativa and has anxiolytic properties, but no study has been conducted to evaluate the effects of CBD on anxiety signs and symptoms in patients with Parkinson’s disease (PD). This study aimed to [...]

Lire la suite

MDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study, Jennifer M. Mitchell et al., 2021,

MDMA-assisted therapy for severe PTSD : a randomized, double-blind, placebo-controlled phase 3 study Jennifer M. Mitchell, Michael Bogenschutz, Alia Lilienstein, Charlotte Harrison, Sarah Kleiman6, Kelly Parker-Guilbert7, Marcela Ot’alora G., Wael Garas, Casey Paleos, Ingmar Gorman 11, Christopher Nicholas12, Michael Mithoefer5,9,13, Shannon Carlin, Bruce Poulter 8,9, Ann Mithoefer9, Sylvestre Quevedo2,14, Gregory Wells 14, Sukhpreet S. Klaire, Bessel van der Kolk16, Keren Tzarfaty9, Revital Amiaz17, Ray Worthy18, Scott Shannon, Joshua D. Woolley2, Cole Marta20, Yevgeniy Gelfand21, Emma Hapke, Simon Amar, Yair Wallach, Randall Brown11, Scott Hamilton25, Julie B. Wang5, Allison Coker 1,5, Rebecca Matthews, Alberdina de Boer5, Berra Yazar-Klosinski, Amy Emerson and Rick Doblin Nature Medicine | www.nature.com/naturemedicine, 2021, 1-12. doi : [...]

Lire la suite

Trial of Psilocybin versus Escitalopram for Depression, Robin Carhart-Harris et al., 2021

Trial of Psilocybin versus Escitalopram for Depression Robin Carhart-Harris, Ph.D., Bruna Giribaldi, B.Sc., Rosalind Watts, D.Clin.Psy., Michelle Baker-Jones, B.A., Ashleigh Murphy-Beiner, M.Sc., Roberta Murphy, M.D., Jonny Martell, M.D., Allan Blemings, M.Sc., David Erritzoe, M.D. and David J. Nutt, M.D.New England Journal of Medicine, 2021, 384, 1402-1411Doi : 10.1056/NEJMoa2032994 Abstract Background Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. Methods In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive [...]

Lire la suite

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms, Robin L. Carhart-Harris et al., 2017

Psilocybin for treatment-resistant depression : fMRI-measured brain mechanisms Robin L Carhart-Harris, Leor Roseman, Mark Bolstridge, Lysia Demetriou, J Nienke Pannekoek, Matthew B Wall, Mark Tanner, Mendel Kaelen, John McGonigle, Kevin Murphy, Robert Leech, H Valerie Curran & David J Nutt Nature, Scientific Reports, 2017, 7, 13187 |1-11 Doi : 10.1038/s41598-017-13282-7   Abstract Psilocybin with psychological support is showing promise as a treatment model in psychiatry but its therapeutic mechanisms are poorly understood. Here, cerebral blood flow (CBF) and blood oxygen-level dependent (BOLD) resting-state functional connectivity (RSFC) were measured with functional magnetic resonance imaging (fMRI) before and after treatment with psilocybin (serotonin agonist) for treatment-resistant depression (TRD). [...]

Lire la suite

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique, Dr Christian SUEUR, USSAP – GRECC, avril 2021

Expérimentation clinico-pharmacologique de la prescription de CBD en clinique addictologique Projet CBD Thérapeutique, CSAPA / USSAP Carcassonne, GRECC. Dr Christian SUEUR, avril 2021. 93 pages   Aujourd’hui, il n’est plus tabou au plan international de penser et d’appliquer des prescriptions de cannabinoïdes en clinique psychiatrique et addictologique.[1] En France, lors de la première séance du C.S.S.T. « Évaluation de la pertinence et de la faisabilité de la mise à disposition du cannabis en France », le 12 décembre 2018, c’est « le membre psychiatre » du C.S.S.T., le docteur George Brousse lui-même, qui souhaitait d’emblée « que soit mentionnée l’utilisation potentielle du CBD dans les troubles psychiatriques et de l’addiction, tout [...]

Lire la suite

Psilocybin Delivers ‘Remarkable’ Relief in Severe Depression, Batya Swift Yasgur, Medscape.com, 2020

Psilocybin Delivers 'Remarkable' Relief in Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News, November 05, 2020   Psilocybin, the psychedelic compound in "magic mushrooms," rapidly improves symptoms and produces remission in as little as two sessions for patients with major depression, new research suggests. Results of a small randomized trial showed that treatment with psilocybin was associated with a greater than 50% reduction in depressive symptoms in 67% of study participants. In addition, 71% showed improvement at 4-week follow-up, with more than 50% achieving remission. "The finding that the majority of people whom we treated showed efficacy was quite a remarkable and gratifying finding [...]

Lire la suite

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study, Sarah Edmonds, 2021

Psilocybin Matches SSRI for Moderate-to-Severe Depression in Phase 2 Study Sarah Edmonds Medscape Medical News, April 14, 2021   The psychedelic drug psilocybin performed just as well as a widely used antidepressant in easing the symptoms of major depression, and outperformed the selective serotonin reuptake inhibitor (SSRI) on a range of secondary measures, results of a small-scale phase 2 study show. In a 6-week trial that included 59 patients with moderate-to-severe depression, there was no significant difference between the impact of high-dose psilocybin on the study's primary yardstick — the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16) — and that of selective serotonin reuptake [...]

Lire la suite

‘Magic Mushrooms’ Effective for Severe Depression, Batya Swift Yasgur, medscape.com, 2017

'Magic Mushrooms' Effective for Severe Depression Batya Swift Yasgur, MA, LSW Medscape Medical News © 2017 October 20, 2017   Psilocybin, the psychoactive compound in “magic mushrooms,” is a promising intervention for patients with treatment-resistant depression (TRD) and appears to offer a rapid, sustained effect, new research shows. Investigators led by David Nutt, MD, PhD, professor of neuropsychopharmacology, Imperial College, London, United Kingdom, collected pre- and posttreatment fMRI data on the use of psilocybin in 19 patients with severe major depression who had failed to respond to conventional treatments. The patients experience dramatic improvements in depressive symptoms 1 day following treatment; close to half met criteria for full response at 5 [...]

Lire la suite

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression, Megan Brooks, medscape.com, 2019

FDA Grants Psilocybin Second Breakthrough Therapy Designation for Resistant Depression Megan Brooks Medscape Medical News © 2019 November 25, 2019   The US Food and Drug Administration (FDA) has granted the Usona Institute breakthrough therapy designation for psilocybin for the treatment of major depressive disorder (MDD). This marks the second time the FDA has granted breakthrough designation for psilocybin, the psychoactive ingredient in "magic mushrooms." In October 2018, Compass Pathways received the designation to test the safety and efficacy of psilocybin-assisted therapy for treatment-resistant depression, as reported by Medscape Medical News. "The results from previous studies clearly demonstrate the remarkable potential for psilocybin as a treatment in MDD patients, which Usona is [...]

Lire la suite